Coya Therapeutics Signs an Agreement with Dr. Reddy’s Laboratories to License its Proposed Biosimilar Abatacept to Develop and Commercialize COYA 302
Shots:
- Dr. Reddy’s will receive up front & an additional fee upon achievement of development milestones along with royalties on net sales of COYA 302 within its licensed territory
- The agreement allows Coya's COYA 301 to be licensed to Dr. Reddy's to permit the commercialization of COYA 302 in territories not otherwise granted to Coya. Similar to what Coya owes Dr. Reddy's, Coya will receive royalties on net sales in their territories
- Coya holds an exclusive right to develop & commercialize COYA 302 across multiple neurodegenerative diseases in multiple territories, incl. North & South America, the EU, UK & Japan while Dr. Reddy’s holds an exclusive right for COYA 302 in areas outside of Coya’s territory. Coya plans to file an IND for COYA 302 in H2’23 & will initiate the P-Ib/II trial in ALS shortly
Ref: Bussineswire | Image: Coya Therapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
